Core Viewpoint - Qingmu Technology, a leading domestic internet e-commerce service provider, is enhancing its market competitiveness through a significant acquisition in the health sector by acquiring 65.83% of Vitalis Pharma AS for 2.12 billion RMB [2][3]. Acquisition Details - The acquisition will be executed by Qingmu's wholly-owned subsidiary, Qingmu PTE. LTD., in two steps: purchasing 49.0662% of Vitalis for approximately 1.06 billion RMB and subscribing to 32.9157% of newly issued shares for the same amount [3]. - Vitalis, established in 2005 in Oslo, Norway, specializes in high-end dietary supplements, including products like seal oil, fish oil, astaxanthin, and coenzyme Q10 [3]. Financial Performance of Vitalis - Vitalis reported revenues of 151.43 million NOK and 97.94 million NOK for 2024 and the first half of 2025, respectively, with net profits of 28.55 million NOK and 23.31 million NOK [4]. - The profit target for Vitalis in 2025 is set at no less than 31 million NOK [4]. Performance Commitments - The acquisition includes performance commitments, requiring Vitalis to achieve a net profit of at least 41.85 million NOK by 2027 and 56.50 million NOK by 2028, representing a growth of no less than 35% year-over-year [5]. - The acquisition price of 300 million NOK is expected to create significant goodwill, which carries a risk of impairment [5]. Strategic Goals - The acquisition aims to implement the company's brand incubation and management strategy, enhancing its capabilities in brand management, product development, and supply chain management in the health sector [5]. - Qingmu Technology plans to increase investments in brand incubation and management, focusing on health consumer products through various strategies, including joint ventures and acquisitions of overseas brands [5]. Revenue Growth - In the first half of 2025, Qingmu's brand incubation and management business generated approximately 230 million RMB, marking an 86.5% year-over-year increase, with its contribution to overall revenue rising from 22.9% to 34.8% [6]. - The brands Cumlaude Lab and ZUCCARI significantly contributed to this revenue growth, achieving over 70% and 95% year-over-year increases, respectively [6]. Overall Company Performance - For the first three quarters of 2025, Qingmu Technology reported revenues of 1.021 billion RMB, a 26.34% increase year-over-year, and a net profit of 79.62 million RMB, up 10.22% [7]. - The company's gross margin has improved significantly, reaching 56.33% in the first three quarters of 2025, up 5.25 percentage points from the same period in 2024 [8].

Core Viewpoint - Qingmu Technology (301110) is expanding its business through a significant acquisition, aiming to enhance its brand incubation and management strategy in the health and wellness sector [1][4]. Group 1: Acquisition Details - Qingmu Technology's subsidiary, Qingmu Singapore, signed a share purchase and subscription agreement to acquire 49.07% of the target company's shares from Norsund for 150 million Norwegian Krone (approximately 106 million RMB) and to subscribe for an additional 32.92% of new shares for the same amount [1]. - After the completion of this transaction, Qingmu Singapore will hold a total of 65.83% of the target company, becoming its controlling shareholder, and the target company will be included in Qingmu's consolidated financial statements [1]. Group 2: Business Model and Services - Qingmu Technology provides comprehensive e-commerce services, including e-commerce operation, channel distribution, and retail services, catering to well-known domestic and international brands [1][2]. - The company has established a complete e-commerce ecosystem, collaborating with major platforms such as Tmall, JD.com, Douyin, Xiaohongshu, and Vipshop, and offers a full range of services from traditional e-commerce operations to digital marketing and consumer engagement [2]. Group 3: Growth Strategy - The brand incubation and management business is identified as the company's second growth curve, with a focus on health consumer products. The company plans to invest more in this area and introduce overseas quality brands through various methods, including joint ventures and acquisitions [3]. - The company reported significant revenue growth for its incubated brands, with Cumlaude Lab and ZUCCARI achieving over 70% and 95% year-on-year growth, respectively, in the first half of 2025 [3]. Group 4: Future Outlook - The acquisition aims to strengthen the company's capabilities in brand management, research and development, production, and supply chain management in the health supplement sector, enhancing its competitive edge [4]. - Qingmu Technology aspires to become a "data and technology-driven retail service expert," focusing on the application of new technologies like AI to improve operational efficiency [3].